Aktis Oncology (NASDAQ:AKTS<\/a>) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion. The stock has traded between $14.72 and $34.19 since its January 2026 initial public offering. Aktis holds $517.3 million in cash, with management guiding runway into 2029. It is pre-revenue except for a single collaboration agreement. <\/p>\n Aktis operates an isotope-agnostic miniprotein radioconjugate platform designed to deliver 225Ac, a highly potent alpha-emitting radioisotope. Lead candidate [225Ac]Ac-AKY-1189 targets Nectin-4, the same target as Padcev, with an IND cleared in May 2025 and preliminary Part-1 dose escalation data expected in the first quarter of 2027. Second program [225Ac]Ac-AKY-2519 targets B7-H3, expressed in approximately 90% of mCRPC, 80% of NSCLC, and 70% of small cell lung cancers. <\/p>\n What an Acquirer Would Actually Be Buying <\/p>\n The rights structure is the differentiator. Aktis retains exclusive, worldwide development and commercialization rights to all current product candidates and discovery programs. The Lilly collaboration covers only targets beyond the scope of the unpartnered pipeline. There are no territorial carve-outs on core assets. <\/p>\n Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and AKTS didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n The Lilly Collaboration Agreement includes an upfront license fee of $60.0 million, up to $525.0 million in research, development, regulatory and commercial launch milestones, and up to $630.0 million in sales milestones. The filing inconsistently describes the royalty as “tiered royalties of up to 10%” in one section and “a tiered royalty of up to low-double digits” in another, creating ambiguity about the actual rate. Aktis runs research through initial human imaging studies; Lilly then owns regulatory, clinical development and commercialization. Lilly may terminate on a target-by-target or region-by-region basis upon 60 days’ prior written notice. Its license is limited to products that contain a radioactive isotope. Lilly also indicated interest in purchasing approximately $100.0 million in shares at IPO, making it both partner and shareholder. The S-1 does not spell out change-of-control mechanics, which a third-party bidder would need to diligence. <\/p>\n Ranking the Plausible Acquirers <\/p>\n Novartis (NYSE:NVS<\/a>) has a $294 billion market cap. It saw its radioligand therapy Pluvicto grow 43% in constant currencies during Q2 2026, as management explicitly stated its intention to progress “beyond Pluvicto and Lutathera, hopefully into additional cancer types.” AKY-2519 in mCRPC is directly adjacent. <\/p>\n Eli Lilly (NYSE:LLY<\/a>) trades at $1,225.73. Ricks said, “We expect to remain active in business development while maintaining discipline.” The existing partnership offers information advantage. <\/p>\n Bristol Myers Squibb (NYSE:BMY<\/a>) has a $132.0 billion market cap. Its Boerner stating BD remains “a top allocation priority.” No comparable radiopharmaceutical franchise exists in the portfolio. <\/p>\n What About Private Equity or Alternative Capital? <\/p>\n With no product revenue to lever, a traditional leveraged buyout (LBO) does not fit. Realistic non-strategic paths are royalty monetization on the Lilly stream, private investment in public equity (PIPE) structures, or crossover funds ahead of 2027 readouts. <\/p>\n What to Watch <\/p>\n Analyst consensus is 100% bullish with a target of $34.42; the 24\/7 Wall St. model base case is $42.16 at 0.5 confidence. Catalysts include Q1 2027 AKY-1189 data, 2027 AKY-2519 mCRPC readouts, and the H2 2026 GMP facility. Trial risk is binary; a failed readout removes the takeout premium entirely. <\/p>\n Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and AKTS didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n<\/a> 24\/7 Wall St. Why a Strategic Buyer Would Want It <\/p>\n